Integrated Filing — IndAS



General information about company

Scrip Code 500257
NSE Symbol LUPIN
MSEI Symbol NOTLISTED
ISIN INE326A01037
Name of company Lupin Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 07-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-04-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 07-05-2026   13:45:00
End date and time of board meeting 07-05-2026   19:25:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 12-02-2026
Indicate Company website link for updated RPT policy of the Company https://www.lupin.com/uploads/Policy_on_Related_Party_Transactions_6e91aa0e1d.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The disclosure for the default on Loans and Debt Securities is not applicable to the Company.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 5,23,460.00 19,51,266.00
Other income 8,883.00 31,277.00
Total income 5,32,343.00 19,82,543.00
2 Expenses
(a) Cost of materials consumed 99,553.00 3,67,836.00
(b) Purchases of stock-in-trade 27,458.00 1,19,232.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (3,351.00) 466.00
(d) Employee benefit expense 66,065.00 2,54,488.00
(e) Finance costs 3,877.00 12,147.00
(f) Depreciation, depletion and amortisation expense 17,705.00 70,718.00
(f) Other Expenses
1 Other expenses (Refer note 5 and 6) 1,36,675.00 4,91,598.00
2 Net (gain) / loss on foreign currency transactions (31,101.00) (62,710.00)
Total other expenses 1,05,574.00 4,28,888.00
Total expenses 3,16,881.00 12,53,775.00
3 Total profit before exceptional items and tax 2,15,462.00 7,28,768.00
4 Exceptional items 44,773.00 40,657.00
5 Total profit before tax 2,60,235.00 7,69,425.00
6 Tax expense
7 Current tax 47,112.00 1,35,129.00
8 Deferred tax (3,246.00) (2,360.00)
9 Total tax expenses 43,866.00 1,32,769.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 2,16,369.00 6,36,656.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 2,16,369.00 6,36,656.00
17 Other comprehensive income net of taxes 651.00 (1,708.00)
18 Total Comprehensive Income for the period 2,17,020.00 6,34,948.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 9,144.00 9,144.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 0.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 47.35 139.38
Diluted earnings (loss) per share from continuing operations 47.24 139.01
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 47.35 139.38
Diluted earnings (loss) per share from continuing and discontinued operations 47.24 139.01
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on May 07, 2026. 2. The Board of Directors have, at its meeting held on May 07, 2026 recommended a dividend of Rs. 18 per equity share of the face value of Rs. 2 each aggregating Rs. 8,229.2 million. The recommended dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting. 3. During the quarter ended March 31, 2026, 380,305 year to date 614,066 equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs, resulting in an increase in the paid up equity share capital by Rs. 0.7 million year to date Rs. 1.2 million and securities premium account by Rs. 463.2 million year to date Rs. 719.7 million. 4. Exceptional items a. The Company and its subsidiary are exposed to multiple civil lawsuits alleging anticompetitive behavior related to certain products and a possible violation of federal and state antitrust laws. These lawsuits were combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the quarter ended 31 December 2025, the Company on best estimate recorded a provision of Rs. 4,493.9 million USD 50.0 million towards this litigation without admission of liability or wrongdoing. During the quarter ended 31 March 2026, this provision has been recorded by the subsidiary and consequently reversed in the standalone results. In April 2026, the wholly owned subsidiary settled one of the ongoing dispute for an amount of Rs. 2,654.1 million USD 30.0 million without admission of liability or wrongdoing. b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets and agreed to pay USD 90.0 million. During the quarter ended December 31, 2025 and year ended March 31, 2026, the Company has compensated LPI for the settlement payment of Rs. 1,364.7 million USD 15.0 million made by it and accordingly expensed. The balance amount of USD 75.0 million towards prepaid option has been paid and capitalised by the subsidiary. c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 collectively referred to as the New Labour Codes. The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 496.4 million during the quarter ended December 31, 2025 and year ended March 31, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. d. During the year ended March 31, 2026, the Company has transferred its Over the Counter OTC and API RandD business in India to its wholly owned subsidiaries Lupinlife Consumer Healthcare Limited and Lupin Manufacturing Solutions Limited respectively, as a going concern on slump sale basis for a consideration of Rs. 8,200.0 million and Rs. 180.0 million resulting in gain on divestment of Rs. 6,589.6 million and Rs. 37.2 million respectively. As at March 31, 2025, assets and liabilities related to transfer of such business were shown as Assets held for sale. e. During the year ended March 31, 2026, the Company has determined that the carrying value of investment in a subsidiary is higher than the recoverable amount and has provided for diminution in the value of investment of Rs. 700.0 million. During the year ended March 31, 2025, the Company had provided for diminution in the value of investments in subsidiaries of Rs. 772.2 million. 5. During the year ended March 31, 2025, the Company has transferred its generic business in India to its wholly owned subsidiary Lupin Life Sciences Limited formerly known as Lupin Atharv Ability Limited, as a going concern on slump sale basis resulting in loss on divestment of Rs. 6.4 million. 6. During the year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of Rs. 750.5 million USD 9.0 million in connection with the drug Glumetza without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. 7. During the quarter and year ended March 31, 2025, the Company has recognised an impairment charge of Rs. 410.9 million related to property, plant and equipment, commercialised intangibles and capital work in progress. 8. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter ended December 31, 2025 and December 31, 2024 respectively.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3,16,851.00
Capital work-in-progress 42,943.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 1,07,673.00
Intangible assets under development 9,317.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 12,20,055.00
Trade receivables, non-current 0.00
Loans, non-current 12,711.00
Other non-current financial assets
1 Other non-current financial assets 2,60,526.00
Total of other non-current financial assets 2,60,526.00
Total non-current financial assets 14,93,292.00
Deferred tax assets (net) 0.00
Other non-current assets
1 Other non-current assets 80,707.00
Total of other non-current assets 80,707.00
Total non-current assets 20,50,783.00
2 Current assets
Inventories 3,35,078.00
Current financial asset
Current investments 3,42,477.00
Trade receivables, current 6,92,203.00
Cash and cash equivalents 11,163.00
Bank balance other than cash and cash equivalents 1,644.00
Loans, current 10,237.00
Other current financial assets
Total of other current financial assets 64,059.00
Total current financial assets 11,21,783.00
Current tax assets (net) 43.00
Other current assets
1 Other current assets 1,02,602.00
Total of other current assets 1,02,602.00
Total current assets 15,59,506.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 36,10,289.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 9,144.00
Other equity 30,04,233.00
Total equity attributable to owners of parent 30,13,377.00
Non controlling interest
Total equity 30,13,377.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 42,225.00
Total of other non-current financial liabilities 42,225.00
Total non-current financial liabilities 42,225.00
Provisions, non-current 45,278.00
Deferred tax liabilities (net) 12,251.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 13,925.00
Total of other non-current liabilities 13,925.00
Total non-current liabilities 1,13,679.00
Current liabilities
Current financial liabilities
Borrowings, current 57,688.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 13,350.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,39,524.00
Total Trade payable 2,52,874.00
Other current financial liabilities
1 Other current financial liabilities 61,114.00
Total of other current financial liabilities 61,114.00
Total current financial liabilities 3,71,676.00
Other current liabilities 38,557.00
1 Other current liabilities 38,557.00
Total of other current liabilities 38,557.00
Provisions, current 17,339.00
Current tax liabilities (Net) 55,661.00
Deferred government grants, Current 0.00
Total current liabilities 4,83,233.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 5,96,912.00
Total equity and liabilites 36,10,289.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss 464.00 618.00
Total Amount of items that will not be reclassified to profit and loss 464.00 618.00
2 Income tax relating to items that will not be reclassified to profit or loss 162.00 216.00
3 Amount of items that will be reclassified to profit and loss
1 (i) Items that will be reclassified subsequently to profit or loss 537.00 (3,243.00)
Total Amount of items that will be reclassified to profit and loss 537.00 (3,243.00)
4 Income tax relating to items that will be reclassified to profit or loss 188.00 (1,133.00)
5 Total Other comprehensive income 651.00 (1,708.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 7,69,425.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 12,147.00
Adjustments for decrease (increase) in inventories (13,673.00)
Adjustments for decrease (increase) in trade receivables, current (87,745.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (32,946.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 52,715.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 15,475.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 70,718.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 7,000.00
Adjustments for provisions, current 2,919.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (38,149.00)
Adjustments for dividend income 0.00
Adjustments for interest income 7,978.00
Adjustments for share-based payments 1,312.00
Adjustments for fair value losses (gains) (5,615.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (9,416.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (66,617.00)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (99,853.00)
Net cash flows from (used in) operations 6,69,572.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,15,587.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 5,53,985.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 3,86,267.00
Other cash receipts from sales of equity or debt instruments of other entities 13,92,612.00
Other cash payments to acquire equity or debt instruments of other entities 16,20,099.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 26,061.00
Purchase of property, plant and equipment 71,704.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 17,500.00
Cash receipts from repayment of advances and loans made to other parties 10,500.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 7,674.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 93,834.00
Net cash flows from (used in) investing activities (5,64,889.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 1,646.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 57,688.00
Repayments of borrowings 0.00
Payments of lease liabilities 9,538.00
Dividends paid 54,834.00
Interest paid 7,075.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (12,113.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (23,017.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (23,017.00)
Cash and cash equivalents cash flow statement at beginning of period 34,180.00
Cash and cash equivalents cash flow statement at end of period 11,163.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 BSR & Co. LLP Yes 31-07-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Advance 0.00 - 0.00 0.00 4,800.00
2 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Advance 0.00 - 0.00 198.30 148.30
3 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Advance 0.00 - 4,800.00 0.00 0.00
4 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Inter-corporate deposit 0.00 - 0.00 74.00 74.00
5 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Interest received 0.00 - 0.30 0.00 0.00
6 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Interest received 0.00 - 498.60 0.00 0.00
7 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Interest received 0.00 - 294.00 0.00 0.00
8 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Interest received 0.00 - 0.30 0.00 0.00
9 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Investment 0.00 - 3,999.90 0.00 0.00
10 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Investment 0.00 - 2,010.00 0.00 0.00
11 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Investment 0.00 - 28,500.00 0.00 0.00
12 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Investment 0.00 - 90,000.00 0.00 0.00
13 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Investment 0.00 - 0.00 3,28,055.60 3,28,055.60
14 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Investment 0.00 - 0.00 333.20 333.20
15 Lupin Limited Lupin Biologics Limited, India Wholly -Owned Subsidiary Investment 0.00 - 0.00 15.00 15.00
16 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Investment 0.00 - 0.00 39,816.70 43,816.60
17 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Investment 0.00 - 0.00 18,854.00 25,000.00
18 Lupin Limited Lupin Lanka (Private) Ltd., Sri Lanka Wholly -Owned Subsidiary Investment 0.00 - 0.00 167.50 167.50
19 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Investment 0.00 - 0.00 2,510.00 2,510.00
20 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Investment 0.00 - 0.00 85,950.00 1,14,450.00
21 Lupin Limited Lupin Oncology Inc., USA Subsidiary Investment 0.00 - 0.00 7,692.80 11,278.50
22 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Investment 0.00 - 0.00 137.90 137.90
23 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Investment 0.00 - 0.00 10.00 90,010.00
24 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Investment 0.00 - 0.00 6,12,654.50 6,12,654.50
25 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Loan 0.00 - 0.00 12,500.00 12,500.00
26 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Loan 0.00 - 0.00 10,000.00 10,000.00
27 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Loan 0.00 - 100.00 0.00 0.00
28 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Loan 0.00 - 10,000.00 0.00 0.00
29 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Loan 0.00 - 400.00 0.00 0.00
30 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Loan 0.00 - 100.00 0.00 0.00
31 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Loan 0.00 - 10,000.00 0.00 0.00
32 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Loan 0.00 - 400.00 0.00 0.00
33 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 5,722.40 0.00 0.00
34 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 377.10 0.00 0.00
35 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Purchase of fixed assets 0.00 - 333.10 0.00 0.00
36 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Purchase of goods or services 0.00 - (0.10) 0.00 0.00
37 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 22,101.10 0.00 0.00
38 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 5.40 0.00 0.00
39 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 0.10 0.00 0.00
40 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Purchase of goods or services 2,400.00 Approved 570.40 0.00 0.00
41 Lupin Limited Mr. Nilesh D. Gupta Key Management Personnel Remuneration 1,800.00 Approved 573.20 0.00 0.00
42 Lupin Limited Mrs. Manju D. Gupta Non- Executive Directors Remuneration 65.00 Approved 56.00 0.00 0.00
43 Lupin Limited Ms.Vinita Gupta Key Management Personnel Remuneration 4,000.00 Approved 1,594.30 0.00 0.00
44 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 2,835.40 0.00 0.00
45 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Sale of goods or services 0.00 - 16.70 0.00 0.00
46 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Sale of goods or services 0.00 - 26.70 0.00 0.00
47 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Sale of goods or services 0.00 - 1,196.80 0.00 0.00
48 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 2,593.70 0.00 0.00
49 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 1,802.30 0.00 0.00
50 Lupin Limited Lupin Oncology Inc., USA Subsidiary Sale of goods or services 8,000.00 Approved 1,433.70 0.00 0.00
51 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Sale of goods or services 0.00 - 368.40 0.00 0.00
52 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Sale of goods or services 0.00 - 6,919.50 0.00 0.00
53 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Sale of goods or services 0.00 - 7,488.70 0.00 0.00
54 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Sale of goods or services 0.00 - 7,527.90 0.00 0.00
55 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Sale of goods or services 0.00 - 24,160.40 0.00 0.00
56 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 50,926.60 0.00 0.00
57 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Sale of goods or services 0.00 - 117.10 0.00 0.00
58 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 307.80 0.00 0.00
59 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Sale of goods or services 0.00 - (23.90) 0.00 0.00
60 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Sale of goods or services 0.00 - 1,047.20 0.00 0.00
61 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 3,35,883.10 0.00 0.00
62 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Sale of goods or services 0.00 - 1,130.20 0.00 0.00
63 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 50.30 0.00 0.00
64 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Sale of goods or services 3,500.00 Approved 191.80 0.00 0.00
65 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Sale of goods or services 0.00 - 8,404.90 0.00 0.00
66 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 457.60 0.00 0.00
67 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 143.20 0.00 0.00
68 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 210.10 0.00 0.00
69 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 81.30 0.00 0.00
70 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 6.50 0.00 0.00
71 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 1,194.10 0.00 0.00
72 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 759.60 0.00 0.00
73 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 6.00 0.00 0.00
74 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 4,082.70 0.00 0.00
75 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 271.80 0.00 0.00
76 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Purchase of goods or services 500.00 Approved 154.30 0.00 0.00
77 Lupin Limited TeamLease Services Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Purchase of goods or services 1,000.00 Approved 484.60 0.00 0.00
78 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Sale of goods or services 0.00 - 77.10 0.00 0.00
79 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Sale of goods or services 0.00 - 25.70 0.00 0.00
80 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Sale of goods or services 0.00 - 17.40 0.00 0.00
81 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Sale of goods or services 0.00 - 2.40 0.00 0.00
82 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 111.10 0.00 0.00
83 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 6.00 0.00 0.00
84 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Sale of goods or services 0.00 - 4.40 0.00 0.00
85 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Sale of goods or services 0.00 - 22.80 0.00 0.00
86 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 23.90 0.00 0.00
87 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Sale of goods or services 0.00 - 512.60 0.00 0.00
88 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 20.20 0.00 0.00
89 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 1,191.80 0.00 0.00
90 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Sale of goods or services 0.00 - 2.40 0.00 0.00
91 Lupin Limited Lupin Oncology Inc., USA Subsidiary Sale of goods or services 3.00 Approved 0.40 0.00 0.00
92 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Sale of goods or services 0.00 - 49.80 0.00 0.00
93 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 265.40 0.00 0.00
94 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Sale of goods or services 0.00 - 9.60 0.00 0.00
95 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 38.60 0.00 0.00
96 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 16.10 0.00 0.00
97 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Sale of goods or services 100.00 Approved 31.90 0.00 0.00
98 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Sale of goods or services 0.00 - 14.00 0.00 0.00
99 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 37.30 0.00 0.00
100 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Sale of goods or services 0.00 - 45.00 0.00 0.00
101 Lupin Limited Southern Cross Pharma Pty Ltd., Australia Wholly -Owned Subsidiary Sale of goods or services 0.00 - 5.40 0.00 0.00
102 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Purchase of goods or services 6,000.00 - 1,199.30 0.00 0.00
103 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Sale of goods or services 0.00 - 0.00 0.00 0.00
104 Lupin Manufacturing Solutions Limited, India Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Sale of goods or services 0.00 - 1,417.90 0.00 0.00
105 Lupin Manufacturing Solutions Limited, India Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Purchase of goods or services 0.00 - 332.10 0.00 0.00
106 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Investment 0.00 - 0.00 16,659.50 16,659.50
107 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Purchase of goods or services 0.00 - 0.90 0.00 0.00
108 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Purchase of goods or services 0.00 - 725.10 0.00 0.00
109 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Interest received 0.00 - 2.10 0.00 0.00
110 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Loan 0.00 - 650.40 0.00 650.40
111 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Investment 0.00 - 0.00 253.00 253.00
112 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Loan 0.00 - 0.00 3,618.60 3,485.30
113 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Loan 0.00 - 885.00 0.00 0.00
114 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Loan 0.00 - 1,558.10 0.00 0.00
115 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Loan 0.00 - 2,868.00 0.00 0.00
116 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Loan 0.00 - 0.00 23,009.10 20,858.40
117 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Loan 0.00 - 3,893.00 0.00 0.00
118 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Loan 0.00 - 0.00 22,681.40 27,534.50
119 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Loan 0.00 - 0.00 23,737.50 24,650.90
120 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Loan 0.00 - 0.00 0.00 18,962.20
121 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Loan 0.00 - 17,694.00 0.00 0.00
122 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Investment 0.00 - 0.00 61,495.50 61,495.50
123 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Investment 0.00 - 0.00 1,726.20 1,726.20
124 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Investment 0.00 - 0.00 2,797.50 2,797.50
125 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Investment 0.00 - 0.00 2,507.60 2,507.60
126 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Investment 0.00 - 0.00 9,170.10 18,327.70
127 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Investment 0.00 - 0.00 41,702.50 41,702.50
128 Lupin Atlantis Holdings SA, Switzerland Lymed S.A.S., France Fellow Subsidiary Investment 0.00 - 0.00 9,170.10 0.00
129 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Interest received 0.00 - 84.60 0.00 0.00
130 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Interest received 0.00 - 716.60 0.00 0.00
131 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Interest received 0.00 - 380.90 0.00 0.00
132 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Interest received 0.00 - 503.80 0.00 0.00
133 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Interest received 0.00 - 79.40 0.00 0.00
134 Lupin Atlantis Holdings SA, Switzerland Generic Health Pty Limited, Australia Fellow Subsidiary Sale of goods or services 0.00 - 22.40 0.00 0.00
135 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Sale of goods or services 0.00 - 2,197.50 0.00 0.00
136 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Sale of goods or services 0.00 - 2,172.30 0.00 0.00
137 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services 0.00 - 13,270.90 0.00 0.00
138 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Sale of goods or services 0.00 - 1,538.00 0.00 0.00
139 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Loan 0.00 - 0.00 782.40 545.00
140 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Loan 0.00 - 163.30 0.00 0.00
141 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Interest received 0.00 - 8.00 0.00 0.00
142 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Loan 0.00 - 0.00 7,103.10 7,190.10
143 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Loan 0.00 - (266.10) 0.00 0.00
144 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Interest received 0.00 - 201.40 0.00 0.00
145 Nanomi B.V., Netherlands Generic Health Pty Limited, Australia Fellow Subsidiary Investment 0.00 - 0.00 11,886.70 11,886.70
146 Nanomi B.V., Netherlands Hormosan Pharma GmbH, Germany Fellow Subsidiary Investment 0.00 - 0.00 3,107.40 3,107.40
147 Nanomi B.V., Netherlands Hormosan Pharma GmbH, Germany Fellow Subsidiary Dividend received 0.00 - 10,260.70 0.00 0.00
148 Nanomi B.V., Netherlands Lupin Philippines, Inc., Philippines Fellow Subsidiary Dividend received 0.00 - 155.70 0.00 0.00
149 Nanomi B.V., Netherlands Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Investment 0.00 - 0.00 68,787.80 68,787.80
150 Nanomi B.V., Netherlands Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Investment 0.00 - 0.00 2,505.60 2,505.60
151 Nanomi B.V., Netherlands Lupin Mexico S.A. de C.V., Mexico Fellow Subsidiary Investment 0.00 - 0.00 64.50 64.50
152 Nanomi B.V., Netherlands Lupin Philippines, Inc., Philippines Fellow Subsidiary Investment 0.00 - 0.00 598.90 598.90
153 Nanomi B.V., Netherlands Generic Health SDN. BHD., Malaysia Fellow Subsidiary Investment 0.00 - 0.00 0.00 15.10
154 Nanomi B.V., Netherlands Lupin Inc., USA Fellow Subsidiary Investment 0.00 - 0.00 6,72,687.60 6,72,687.60
155 Nanomi B.V., Netherlands Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 5,181.50 0.00 0.00
156 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Investment 0.00 - 0.00 13,167.10 4,683.70
157 Lupin Healthcare (UK) Limited, UK Renascience Pharma Limited, UK Fellow Subsidiary Sale of goods or services 0.00 - 579.40 0.00 0.00
158 Lupin Pharmaceuticals, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 2,163.60 0.00 0.00
159 Lupin Pharmaceuticals, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 192.90 0.00 0.00
160 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 73.40 0.00 0.00
161 Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 14.50 0.00 0.00
162 Lupin Pharmaceuticals, Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Purchase of goods or services 0.00 - 5,181.50 0.00 0.00
163 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 39.30 0.00 0.00
164 Lupin Research Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 25,983.60 0.00 0.00
165 Novel Laboratories, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 9,699.20 0.00 0.00
166 Novel Laboratories, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 27,017.90 0.00 0.00
167 Novel Laboratories, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Purchase of goods or services 0.00 - (3.90) 0.00 0.00
168 Lupin Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Sale of goods or services 0.00 - 65.90 0.00 0.00
169 Lupin Inc., USA Lupin Atlantis Holdings SA, Switzerland Fellow Subsidiary Sale of goods or services 0.00 - 67.60 0.00 0.00
170 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 279.80 0.00 0.00
171 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Sale of goods or services 0.00 - 108.50 0.00 0.00
172 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services 0.00 - (1,259.90) 0.00 0.00
173 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services 0.00 - 57.00 0.00 0.00
174 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 1,46,216.30 0.00 0.00
175 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 517.00 0.00 0.00
176 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 54.70 0.00 0.00
177 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 97.00 0.00 0.00
178 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services 0.00 - 7.20 0.00 0.00
179 Lupin Inc., USA Lupin Australia Pty Limited, Australia Fellow Subsidiary Sale of goods or services 0.00 - 2.20 0.00 0.00
180 Lupin Management, Inc., USA Generic Health Pty Limited, Australia Fellow Subsidiary Sale of goods or services 0.00 - 26.50 0.00 0.00
181 Lupin Management, Inc., USA Lupin Atlantis Holdings SA, Switzerland Fellow Subsidiary Sale of goods or services 0.00 - 378.80 0.00 0.00
182 Lupin Management, Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Sale of goods or services 0.00 - 136.60 0.00 0.00
183 Lupin Management, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 4,430.10 0.00 0.00
184 Lupin Management, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Sale of goods or services 0.00 - 443.30 0.00 0.00
185 Lupin Management, Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Sale of goods or services 200.00 Approved 58.80 0.00 0.00
186 Lupin Management, Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services 0.00 - 85.50 0.00 0.00
187 Lupin Management, Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 905.40 0.00 0.00
188 Lupin Management, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - 145.10 0.00 0.00
189 Lupin Management, Inc., USA Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Sale of goods or services 0.00 - 165.90 0.00 0.00
190 Lupin Management, Inc., USA Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Sale of goods or services 0.00 - 133.00 0.00 0.00
191 Lupin Management, Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Sale of goods or services 0.00 - 1,256.80 0.00 0.00
192 Lupin Management, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 - (17.50) 0.00 0.00
193 Lupin Management, Inc., USA Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Sale of goods or services 0.00 - (16.40) 0.00 0.00
194 Lupin Management, Inc., USA Lupin Nz Ltd., New Zealand Fellow Subsidiary Sale of goods or services 0.00 - 15.70 0.00 0.00
195 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Loan 0.00 - 0.00 9,860.40 0.00
196 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Investment 0.00 - 0.00 37,837.40 38,971.60
197 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Investment 0.00 - 0.00 6,104.20 62,364.00
198 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Investment 0.00 - 0.00 7,691.00 26,705.00
199 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Investment 0.00 - 0.00 61,725.70 98,324.10
200 Laboratorios Grin, S.A. de C.V., Mexico Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Sale of goods or services 0.00 - 7.40 0.00 0.00
201 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 73.50 54.70
202 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 146.70 193.00
203 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 90.10 60.30
204 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 129.90 253.10
205 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 36.30 13.50
206 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 1.60 9.00
207 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 394.10 480.80
208 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 2,077.50 2,266.60
209 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 3,808.10 3,782.70
210 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 254.80 3.70
211 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 3,001.10 5,710.00
212 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 5,627.40 10,317.60
213 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 6.00 12.90
214 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 650.50 571.00
215 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 8,147.90 23,135.20
216 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 14,616.30 7,781.40
217 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 2.00 2.10
218 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Creditors 0.00 - 0.00 0.00 85.30
219 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 (159.30) 84.00
220 Lupin Limited S. N. Pharma Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors 0.00 - 0.00 0.00 0.20
221 Lupin Limited Shuban Prints Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors 0.00 - 0.00 0.10 0.00
222 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors 0.00 - 0.00 52.30 43.10
223 Lupin Limited TeamLease Services Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors 0.00 - 0.00 5.80 0.00
224 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors 0.00 - 0.00 0.60 0.00
225 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 4,277.20 4,617.70
226 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 3,991.30 6,774.90
227 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 5,960.80 5,772.30
228 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 13,463.20 22,044.20
229 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 47,161.40 82,620.90
230 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 90.10 52.10
231 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 1,860.00 118.60
232 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 138.50 (226.90)
233 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 7,700.90 4,573.90
234 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 4,40,880.00 4,39,526.40
235 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 7,589.70 7,480.10
236 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 20.50 51.60
237 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 2.50 0.00
238 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 5,412.20 16.20
239 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 4,323.10 6,781.00
240 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Deposits received balance Premises 0.00 - 0.00 30.00 30.00
241 Lupin Limited Polynova Industries Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Deposits received balance Premises 0.00 - 0.00 1.00 1.00
242 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 1,805.90 25.20
243 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 (0.60) 39.00
244 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 38.30 62.10
245 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 74.10 116.30
246 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 30.30 138.10
247 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 65.30 61.10
248 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 30.40 33.20
249 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 2,047.10 50.60
250 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 1.60 0.60
251 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 1,091.40 493.70
252 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 101.10 117.80
253 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 0.30 0.00
254 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 (47.80) 16.30
255 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 443.30 140.90
256 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 0.10 0.00
257 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 22.30 133.80
258 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 299.90 2.50
259 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 137.50 27.80
260 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 24.20 21.70
261 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 19.60 126.40
262 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 63.30 56.90
263 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 26.10 22.50
264 Lupin Limited TeamLease Services Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Expenses receivable 0.00 - 0.00 0.00 0.10
265 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expns Payable 0.00 - 0.00 530.90 279.90
266 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 11.80 0.00 0.00
267 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 28.60 0.00 0.00
268 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 35.50 0.00 0.00
269 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 127.50 0.00 0.00
270 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 616.90 0.00 0.00
271 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 344.70 0.00 0.00
272 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 443.00 0.00 0.00
273 Lupin Limited Lupin Investments Pvt. Limited Entity having significant influence over the company Any other transaction Expns Reimbursed 10.00 Approved 0.20 0.00 0.00
274 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 0.50 0.00 0.00
275 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 3,348.20 0.00 0.00
276 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 47.60 0.00 0.00
277 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 343.70 0.00 0.00
278 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - 20,476.50 0.00 0.00
279 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - (85.60) 0.00 0.00
280 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Expns Reimbursed 0.00 - (0.10) 0.00 0.00
281 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Expns Reimbursed 100.00 Approved 16.10 0.00 0.00
282 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Guarantee Fees Income 0.00 - 333.20 0.00 0.00
283 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Guarantee Fees Income 0.00 - 85.80 0.00 0.00
284 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Guarantee Fees Income 0.00 - 230.10 0.00 0.00
285 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Income from assignment of Rights 0.00 - 1.20 0.00 0.00
286 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 40.50 42.90
287 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 14.30 13.70
288 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 249.90 539.50
289 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 0.60 1.50
290 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 38.90 61.70
291 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 7.60 9.20
292 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 2.10 2.50
293 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 12.70 12.00
294 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 1,564.70 1,472.20
295 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 483.70 650.30
296 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 17.80 10.90
297 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 3,510.70 2,531.70
298 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 0.70 1.40
299 Lupin Limited Lupin Oncology Inc., USA Subsidiary Any other transaction Income Receivable 0.00 - 0.00 1,361.70 2,525.00
300 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 81.50 26.50
301 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 653.40 321.90
302 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 4.70 5.00
303 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 36.50 22.40
304 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 82,001.30 10.20
305 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 156.00 45.00
306 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Income Receivable 0.00 - 0.00 14.20 16.80
307 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 119.40 493.30
308 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 45.30 20.00
309 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 33.00 23.30
310 Lupin Limited Southern Cross Pharma Pty Ltd., Australia Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 1.90 3.00
311 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 56.30 0.00 0.00
312 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 130.00 0.00 0.00
313 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 102.10 0.00 0.00
314 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 181.50 0.00 0.00
315 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 228.80 0.00 0.00
316 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 125.70 0.00 0.00
317 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 67.80 0.00 0.00
318 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 76.50 0.00 0.00
319 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 16.10 0.00 0.00
320 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 1,219.90 0.00 0.00
321 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 209.00 0.00 0.00
322 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 4.30 0.00 0.00
323 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 46.10 0.00 0.00
324 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 1,053.50 0.00 0.00
325 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - (912.30) 0.00 0.00
326 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 143.70 0.00 0.00
327 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 30.10 0.00 0.00
328 Lupin Limited Medisol S.A.S., France Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 2.00 0.00 0.00
329 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 58.10 0.00 0.00
330 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Recoveries 200.00 Approved 44.60 0.00 0.00
331 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 133.70 0.00 0.00
332 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 128.80 0.00 0.00
333 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 45.00 0.00 0.00
334 Lupin Limited Polynova Industries Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Recoveries 0.00 - 2.30 0.00 0.00
335 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Recoveries 0.00 - 0.60 0.00 0.00
336 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Rent expense 140.00 Approved 62.20 0.00 0.00
337 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Rent Income 0.00 - 30.00 0.00 0.00
338 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Rent Income 0.00 - 689.30 0.00 0.00
339 Lupin Limited Polynova Industries Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Rent Income 25.00 Approved 8.10 0.00 0.00
340 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 0.00 5,000.00 5,000.00
341 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 0.00 500.00 500.00
342 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 0.00 15,000.00 15,000.00
343 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 0.00 2,68,586.00 2,86,804.00
344 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 0.00 5,000.00 5,000.00
345 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 0.00 39,069.60 42,122.00
346 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Guarantees issued by the Company on behalf of subsidiary companies for contractual obligations 0.00 - 0.00 59,452.90 63,486.00
347 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Rent Income 0.00 - 2.80 0.00 0.00
348 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 9.80 0.00 0.00
349 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 7,874.20 7,777.40
350 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 0.60 0.70
351 Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) LUPINLIFE Consumer Healthcare Limited, India Fellow Subsidiary Any other transaction Debtors 0.00 - 0.00 0.00 0.20
352 Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) LUPINLIFE Consumer Healthcare Limited, India Fellow Subsidiary Any other transaction Recoveries 0.00 - 0.20 0.00 0.00
353 Lupin Manufacturing Solutions Limited, India Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 2,484.50 1,850.70
354 Lupin Manufacturing Solutions Limited, India Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 374.10 729.70
355 Lupin Pharma Canada Limited, Canada Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction BUSINESS DEVELOPMENT/COMPLIANCE 0.00 - 0.40 0.00 0.00
356 Lupin Pharma Canada Limited, Canada Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction TRADE PAYABLES 0.00 - 0.00 0.20 0.20
357 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Reimbursement 0.00 - 10.50 0.00 0.00
358 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Receivable 0.00 - 0.00 604.90 380.80
359 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Payable 0.00 - 0.00 19.70 0.00
360 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Any other transaction Trade Receivable 0.00 - 0.00 1,597.90 0.00
361 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Any other transaction Trade Payable 0.00 - 0.00 0.00 1,616.80
362 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Any other transaction Trade Receivable 0.00 - 0.00 0.70 13.10
363 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Any other transaction Trade Payable 0.00 - 0.00 266.40 49.40
364 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Payable 0.00 - 0.00 0.00 2.20
365 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Any other transaction Recoveries 0.00 - 10.80 0.00 0.00
366 Lupin Australia Pty Limited, Australia Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivable 0.00 - 0.00 15.10 16.70
367 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 1,514.80 1,958.60
368 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 (2.60) 0.00
369 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 9.70 335.20
370 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 1,338.60 2,555.50
371 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 131.50 146.10
372 Lupin Atlantis Holdings SA, Switzerland Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 709.40 143.80
373 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 17,827.90 18,709.60
374 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 3,180.10 762.00
375 Lupin Atlantis Holdings SA, Switzerland Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 21.40 2.20
376 Lupin Atlantis Holdings SA, Switzerland YL Biologics Ltd., Japan Jointly Controlled Entity Any other transaction Receivables 0.00 - 0.00 38.70 28.50
377 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 62.10 43.90
378 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 21.60 23.20
379 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 58.30 279.30
380 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 95.30 117.30
381 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 220.60 184.50
382 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 60.00 90.80
383 Lupin Atlantis Holdings SA, Switzerland Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 136.90 246.30
384 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 622.40 492.70
385 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 8.20 0.00
386 Lupin Atlantis Holdings SA, Switzerland Lupin Research Inc., USA Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 223.90 389.40
387 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Other Income 0.00 - 246.00 0.00 0.00
388 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Other Income 0.00 - 286.80 0.00 0.00
389 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Other Income 0.00 - 17.10 0.00 0.00
390 Lupin Atlantis Holdings SA, Switzerland Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Any other transaction Other Income 0.00 - 21.00 0.00 0.00
391 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Other Income 0.00 - 265.30 0.00 0.00
392 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Any other transaction Other Income 0.00 - 31.70 0.00 0.00
393 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 60.80 0.00 0.00
394 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 64.40 0.00 0.00
395 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - (154.70) 0.00 0.00
396 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 9.00 0.00 0.00
397 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 320.20 0.00 0.00
398 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 333.40 0.00 0.00
399 Lupin Atlantis Holdings SA, Switzerland Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 378.80 0.00 0.00
400 Lupin Atlantis Holdings SA, Switzerland Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 275.00 0.00 0.00
401 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 1,058.30 0.00 0.00
402 Lupin Atlantis Holdings SA, Switzerland Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 628.10 0.00 0.00
403 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 207.70 0.00 0.00
404 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 0.60 0.00 0.00
405 Lupin Atlantis Holdings SA, Switzerland YL Biologics Ltd., Japan Jointly Controlled Entity Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 11.40 0.00 0.00
406 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 103.90 31.00
407 Hormosan Pharma GmbH, Germany Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Capital Contributions 0.00 - 5,370.70 0.00 0.00
408 Hormosan Pharma GmbH, Germany Medisol S.A.S., France Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 0.00 27.80
409 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Payables 0.00 - 0.00 140.20 114.90
410 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Other Income 0.00 - 90.60 0.00 0.00
411 Hormosan Pharma GmbH, Germany Medisol S.A.S., France Fellow Subsidiary Any other transaction Other Income 0.00 - 26.20 0.00 0.00
412 Nanomi B.V., Netherlands Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 1,536.10 0.00 0.00
413 Nanomi B.V., Netherlands Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 161.60 0.00 0.00
414 Nanomi B.V., Netherlands Medisol S.A.S., France Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 431.10 0.00 0.00
415 Lupin Pharmaceuticals, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Product Liability 0.00 - 211.10 0.00 0.00
416 Lupin Pharmaceuticals, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 1,158.40 0.00 0.00
417 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 116.60 0.00 0.00
418 Lupin Pharmaceuticals, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 211.90 0.00 0.00
419 Lupin Pharmaceuticals, Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 12.50 0.00 0.00
420 Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 474.60 0.00 0.00
421 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 1,070.40 0.00 0.00
422 Lupin Research Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 170.80 0.00 0.00
423 Lupin Research Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 11.20 0.00 0.00
424 Lupin Research Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - (1.50) 0.00 0.00
425 Novel Laboratories, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 0.30 0.00 0.00
426 Novel Laboratories, Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 240.20 0.00 0.00
427 Novel Laboratories, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 5.30 0.00 0.00
428 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 733.70 0.00 0.00
429 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 11.10 0.00 0.00
430 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 25.90 0.00 0.00
431 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 6.20 0.00 0.00
432 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 2,103.40 0.00 0.00
433 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 479.60 0.00 0.00
434 Lupin Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 2,201.80 0.00 0.00
435 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 1,665.60 0.00 0.00
436 Lupin Inc., USA Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 - 3.00 0.00 0.00
437 Lupin Management, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 210.60 0.00 0.00
438 Lupin Management, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 - 1.10 0.00 0.00
439 Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 144.00 296.60
440 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 136.70 0.00
441 Novel Laboratories, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 0.80 2.90
442 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 900.90 15.70
443 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 1,617.00 0.00
444 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 28,605.50 19,559.10
445 Lupin Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 0.50 2,302.70
446 Lupin Management, Inc., USA Generic Health Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 24.30 1.80
447 Lupin Management, Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 44.20 93.60
448 Lupin Management, Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 10.70 48.20
449 Lupin Management, Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 45.00 0.00
450 Lupin Management, Inc., USA Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 182.40 370.90
451 Lupin Management, Inc., USA Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 19.30 104.60
452 Lupin Management, Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 127.00 1,190.80
453 Lupin Management, Inc., USA Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 49.30 26.70
454 Lupin Management, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 723.50 1,239.50
455 Lupin Pharmaceuticals, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 84.40 261.80
456 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 24.00 754.20
457 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 0.00 21.90
458 Lupin Research Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 156.10 45.80
459 Novel Laboratories, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 124.30 118.60
460 Lupin Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 20.40 0.00
461 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 120.90 626.00
462 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 26.60 0.00
463 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 1,50,923.60 1,52,313.80
464 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 37,121.40 43,696.10
465 Lupin Research Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 9.50 0.00
466 Lupin Research Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 3.20 0.00
467 Novel Laboratories, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 54.00 3.90
468 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 22.20 35.60
469 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 0.00 55.50
470 Lupin Pharmaceuticals, Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 0.00 454.00
471 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 0.00 45.70
472 Lupin Inc., USA Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 0.00 3.20
473 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 0.00 7.90
474 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 0.00 209.20
475 Lupin Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 0.00 23.90
476 Lupin Inc., USA Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Payables 0.00 - 0.00 0.00 2.40
477 Lupin Management, Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 0.00 44.80
478 Lupin Management, Inc., USA Lupin Nz Ltd., New Zealand Fellow Subsidiary Any other transaction Trade Receivables 0.00 - 0.00 0.00 16.80
479 Lupin Healthcare (UK) Limited, UK Renascience Pharma Limited, UK Fellow Subsidiary Any other transaction Receivables 0.00 - 0.00 0.00 611.90
Total value of transaction during the reporting period 9,93,655.70